Oral Oncology, Target Therapy

Gefitinib (Gefitinib)

Patient Selection  Select patients for the first-line treatment of metastatic NSCLC with gefitinib based on the presence of EGFR exon 19 deletions or exon 21 L858R mutations in their tumor or pl...

Dasatinib (Dasanib)

• Dosage of Dasatinin in Adult Patients: -The recommended starting dosage of Dasatinib for chronic phase CML in adults is 100 mg  administered orally once daily.  -The recommended st...

Imatinib (Imatinib)

Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML): Oral: Chronic phase: 400 mg once daily; may be increased to 600 mg daily, if tolerated, for disease progression, lack of hem...

Kitent (Sunitinib)

GIST and Advanced RCC: •50 mg orally once daily, with or without food, 4 weeks on treatment followed by 2 weeks off. Adjuvant RCC: •50 mg orally once daily, with or without food, 4 we...

Kimotar (Erlotinib)

Treatment of locally advanced or metastatic non-small cell lung cancer 150 mg daily. Dosage reduction may be required for patients with hepatic impairment. Pancreatic Cancer, treatment of lo...

Kimonil(Nilotinib)

Recommended Adult Dose: Newly diagnosed Ph+ CML-CP: 300 mg orally twice daily. Resistant or intolerant Ph+ CML-CP and CML-AP: 400 mg orally twice daily. (2.1) Recommended Pediatric Dose: Newly Diagn...

Soranex(Sorafenib)

400 mg (2 tablets) orally twice daily without food. Treatment interruption and/or dose reduction may be needed to manage suspected adverse drug reactions

For Experts & healthcare professionals

How is technology impacting the quality assurance of our products

in our manufacturing sites many different types of technologies are being implemented to improve the processes of pharmaceutical manufacturing and Quality Assurance which ultimately, creates a safer medicine...

Our focus, high quality targeted medicines

At Kimia Pharmaceuticals, we are focused on medicine development in key cancer areas where there are patient needs. Our goal is to bring much needed new treatments to people with cancer.

Visit our scientific blogs ONCOMED

ASCO 2020 Gastrointestinal Cancers Symposium

Read breaking news and watch expert interviews from most recent american society of c...

2020 Genitourinary Cancers Symposium

Read breaking news and watch expert interviews from most recent american society of c...


ONCOGENE

Molecular Diagnostics in Colorectal Carcinoma

Watch related videos for expert opinions and download guidelines in OncoGene online m...

BCR-ABL mutations and CML treatment

BCR-ABL1 mutations that should NOT be treated with bosutinib, dasatinib or nilotinib ...

About us

To improve medicine availability for the thousands of patients with cancer we established KIMIA PHARMACEUTICALS as a knowledge based Company in 2012.We are focused on Iranian cancer patients treatments needs and grew fast in a competitive market ,Today we are among market leaders in Iran...

Read More
Company Profile

drug's Factory

Company Infrastructure

drug export

Company Personnel

All together we are in constant  motion.                           
Cancer can not stop me & you ,Us !

 Kimia Pharmaceutical Co.